Get started
Work

Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

Year: 2019
Type: article
Study design: Clinical Trial
DOI: 10.1093/annonc/mdz446
Authors: R. Camidge, H.R. Kim, M.-J. Ahn, J.C.-H. Yang, J.-Y. Han, M.J. Hochmair, K.H. Lee, A. Delmonte, M.R. Garcia Campelo, D.-W. Kim, F. Griesinger, E. Felip, R. Califano, A. Spira, S. Gettinger, M. Tiseo, Q. Ni, P. Zhang, S. Popat
Institutions: University of Colorado Cancer Center, Yonsei University, Severance Hospital, Yonsei Cancer Hospital, Samsung Medical Center, National Taiwan University Hospital, National Cancer Center, Ludwig Boltzmann Institute for Lung Health, Otto Wagner Hospital, Chungbuk National University, Chungbuk National University Hospital, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Complexo Hospitalario Universitario A Coruña, Seoul National University, Seoul National University Hospital, Carl von Ossietzky Universität Oldenburg, Pius Hospital Oldenburg, Vall d'Hebron Hospital Universitari, National Health Service, The Christie NHS Foundation Trust, Virginia Cancer Specialists, Yale Cancer Center, Takeda Oncology (United States), Royal Marsden Hospital
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2991075386
FWCI: 5.144
Cites:
Cited by: 34
Related to: 10